Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

被引：65

作者：

Cumming, JG ^{[1
]}

McKenzie, CL ^{[1
]}

Bowden, SG ^{[1
]}

Campbell, D ^{[1
]}

Masters, DJ ^{[1
]}

Breed, J ^{[1
]}

Jewsbury, PJ ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 21期

关键词：

p38 MAP kinase inhibitors;

D O I：

10.1016/j.bmcl.2004.08.007

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyr midines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：5389 / 5394

页数：6

共 28 条

[1] Protein kinase activation and myocardial ischemia/reperfusion injury [J].

Armstrong, SC .

CARDIOVASCULAR RESEARCH, 2004, 61 (03) :427-436

[2] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[3] New inhibitors of p38 kinase [J].

Boehm, JC ;

Adams, JL .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37

[4] Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: Identification and optimisation of substituted 2,4-bis anilino pyrimidines [J].

Breault, GA ;

Ellston, RPA ;

Green, S ;

James, SR ;

Jewsbury, PJ ;

Midgley, CJ ;

Pauptit, RA ;

Minshull, CA ;

Tucker, JA ;

Pease, JE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :2961-2966

[5] A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis [J].

Brown, DS ;

Belfield, AJ ;

Brown, GR ;

Campbell, D ;

Foubister, A ;

Masters, DJ ;

Pike, KG ;

Snelson, WL ;

Wells, SL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (21) :5383-5387

[6]

Cirillo Pier F., 2002, Current Topics in Medicinal Chemistry, V2, P1021, DOI 10.2174/1568026023393390

[7]

CUMMING JG, 2000, Patent No. 0127089

[8] Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].

Davies, SP ;

Reddy, H ;

Caivano, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105

[9] Potential new drugs for therapy of chronic obstructive pulmonary disease [J].

de Boer, WI .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (07) :1067-1086

[10] Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity [J].

Fitzgerald, CE ;

Patel, SB ;

Becker, JW ;

Cameron, PM ;

Zaller, D ;

Pikounis, VB ;

O'Keefe, SJ ;

Scapin, G .

NATURE STRUCTURAL BIOLOGY, 2003, 10 (09) :764-769

← 1 2 3 →